User profiles for M. J. Moore

Melissa J. Moore

- Verified email at umassmed.edu - Cited by 31803

Michael Moore

- Verified email at regeneron.com - Cited by 12839

Michael Moore

- Verified email at whoi.edu - Cited by 12387

[PDF][PDF] Pre-mRNA splicing: awash in a sea of proteins

MS Jurica, MJ Moore - Molecular cell, 2003 - cell.com
What's in a spliceosome? More than we ever imagined, according to recent reports employing
proteomics techniques to analyze this multi-megadalton machine. As of 1999, around 100 …

From birth to death: the complex lives of eukaryotic mRNAs

MJ Moore - Science, 2005 - science.org
Recent work indicates that the posttranscriptional control of eukaryotic gene expression is
much more elaborate and extensive than previously thought, with essentially every step of …

[HTML][HTML] Pre-mRNA processing reaches back totranscription and ahead to translation

MJ Moore, NJ Proudfoot - Cell, 2009 - cell.com
The pathway from gene activation in the nucleus to mRNA translation and decay at specific
locations in the cytoplasm is both streamlined and highly interconnected. This review …

[HTML][HTML] Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

W Li, MJ Moore, N Vasilieva, J Sui, SK Wong… - Nature, 2003 - nature.com
Spike (S) proteins of coronaviruses, including the coronavirus that causes severe acute
respiratory syndrome (SARS), associate with cellular receptors to mediate infection of their target …

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

HA Burris 3rd, MJ Moore, J Andersen… - Journal of clinical …, 1997 - ascopubs.org
PURPOSE Most patients with advanced pancreas cancer experience pain and must limit
their daily activities because of tumor-related symptoms. To date, no treatment has had a …

[PDF][PDF] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of …

MJ Moore, D Goldstein, J Hamm, A Figer… - Journal of clinical …, 2007 - Citeseer
Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

[HTML][HTML] K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

…, L Shepherd, HJ Au, C Langer, MJ Moore… - … England Journal of …, 2008 - Mass Medical Soc
Background Treatment with cetuximab, a monoclonal antibody directed against the epidermal
growth factor receptor, improves overall and progression-free survival and preserves the …

[HTML][HTML] Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer

…, LS Rosen, L Fehrenbacher, MJ Moore… - … England Journal of …, 2000 - Mass Medical Soc
Background The combination of fluorouracil and leucovorin has until recently been standard
therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with …

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized …

…, JT Roberts, L Dogliotti, T Oliver, MJ Moore… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-…

[HTML][HTML] Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

CM Ribic, DJ Sargent, MJ Moore… - … England Journal of …, 2003 - Mass Medical Soc
Background Colon cancers with high-frequency microsatellite instability have clinical and
pathological features that distinguish them from microsatellite-stable tumors. We investigated …